Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
EMJ GOLD
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
£450m invested in UK by AZ and Boehringer
In good news for UK life sciences investment, two companies have made pledges to build new facilities.
Read more
Eli Lilly acquires Kelonia Therapeutics for $7bn
Lilly will gain access to an experimental cancer therapy for multiple myeloma.
OpenAI launches early drug discovery AI model
OpenAI has launched GPT-Rosalind, a domain-specific AI model aimed at improving efficiency in early-stage drug discovery.
Tirzepatide linked to more lean mass loss than semaglutide
The rivalry between Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide continues.
Amazon launches AI platform for faster drug discovery
Amazon Web Services has launched a new AI platform to help drug developers identify and test potential candidates.
Novo partners with OpenAI to boost drug development
Novo Nordisk announced on 14 April 2026 a strategic partnership with OpenAI to boost drug development by streamlining manufacturing, supply chains and distribution.
£6.3m fund targets men’s health gap in England
A new fund has launched to tackle widening health inequalities among underserved men in England.
Biopharma company joins lawsuit over CMS hemp pilot
MMJ International Holdings has joined plaintiffs taking legal action against the CMS.
Novo Nordisk launches higher-dose semaglutide
Novo Nordisk has launched a 7.2 mg semaglutide injection in the US, following FDA approval on 19 March.
Loading posts...
« Previous
1
2
3
4
…
49
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View